| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Human umbilical vein endothelial cell (HUVEC) vaccine is thought to inhibit tumor growth by inhibiting tumor angiogenesis, and we have been conducting the clinical trial of HUVEC vaccine at the Tokyo University Hospital. It was confirmed that HUVEC specific immunity was induced by the vaccine treatment and it was shown that there is a possibility of improving prognosis in the patients with malignant brain tumors. It also showed the possibility of culturing HUVEC in human platelet preparations. Furthermore, comprehensive genome analysis was performed on hemangioblastomas the tumor angiogenesis of which are remarkable. Our study showed the importance of VHL gene abnormality in tumorgenesis of hemangioblastomas. These results will able to lead to the future elucidation of the mechanism of neovascularization and introduction of HUVEC vaccine therapy to hemangioblastomas
|
